Biologics Mixing, Diluting, and Repackaging: FDA Draft Guidance
Boehringer Ingelheim Adalimumab Biosimilar Accepted for Review by FDA and EMA
Biogen's Tecfidera Settles Intellectual Patent Dispute
Pfizer Announces Positive Trial Results for Potential Humira Biosimilar
Bristol-Myers Squibb and GeneCentric Diagnostics Exploring Lung Cancer Biomarker Research
Breaking: US Supreme Court to Hear Biosimilars Lawsuits
Which road will the courts take?
What Lies Ahead for the Big Three RA Drugs?
Bio Relief: US FDA Rules On Biosimilars Naming
The suspense is over: the US Food and Drug Administration (FDA) has made their decision.
News and Views in Healthcare: This Weekend's Top 3 Reads
What's on our radar in the healthcare world.
US FDA Accepts Mylan Biologics License Application (BLA)
Decision slated for early September.
Should Biosimilars Be Interchangeable with Biologics?
Interchangeability is the real question.
News and Views in Healthcare: Today's Top 3 Reads
Today's top healthcare news with a focus on the biosimilars industry.
Biotech Movers and Shakers: Eye on Oncobiologics
We'll feature the latest biotechnolology "movers and shakers"--and how they are impacting the biosimilars industry.
What President Trump Means for Big Pharma
Patients may save money on prescriptions---and cut down pharma's profits.
Medicare Reimbursing for Inflectra, Pfizer's Infliximab Biosimilar
The New Wrinkle in the US Biosimilars Approval Process
GPhA takes issue with FDA timeline.
US Biosimilar Reimbursement: Medicare and Medicaid
Mylan and Momenta Pharma Combine Biosimilar Forces
Mylan and Momenta Pharmaceuticals to develop, manufacture, and commercialize six of Momenta’s current biosimilar candidates.
FDA Finalizes Biosimilar Guidance
Was waiting the worst part?
Biosimilar Shows Promise Treating Chemotherapy-Induced Anemia in Elderly Patients
Developments in Biosimilars for Rheumatic Diseases
Biologic Agents Continue to Outpace Overall Pharma Spending Growth
How Do US Payers View Biosimilars From a Cost Perspective?
US payers do not expect the biosimilars market to be like the generics market.
What Were the Top Five Legal Issues in Biosimilars in 2016?
Branded Trastuzumab HERITAGE Study Published in JAMA
The BPCIA Patent Dance – What Biosimilar Companies Need To Know
Live webcast on what biosimilar companies need to know.
Mundipharma Establishes Disti License from Celltrion
BioCND to Develop Lucentis Biosimilar
What Are the Eight Barriers to Biosimilar Development?
Quality, safety, and knowledge are critical.
Six Months Makes a Difference: Physicians' Attitudes About Biosimilars
A notably larger percentage of US physicians say they intend to prescribe biosimilars in the coming three years.
